A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study()

OBJECTIVE: Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Garcia, Agustin A., Sill, Michael W., Lankes, Heather A., Godwin, Andrew K., Mannel, Robert S., Armstrong, Deborah K., Carolla, Robert L., Liepman, Marcia K., Spirtos, Nick M., Fischer, Edgar G., Leslie, Kimberly K.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3971755/
https://ncbi.nlm.nih.gov/pubmed/22037316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.10.022
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars